GenoMed Prevents Sickle Cell Pain for Over a YearST. LOUIS--(BUSINESS WIRE)--Mar 12, 2007 - GenoMed (OTC Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today publication of a case report of a sickle cell patient whose pain has disappeared for over a year thanks to GenoMed's treatment.
The patient is a middle-aged African American woman who for years required multiple pain pills every day to tolerate the pain of her sickle cell disease. Since beginning GenoMed's trial on Dec. 22, 2005, she experienced no pain until her trial medication accidentally ran out on February 6, 2006. Said her physician, who is lead author on the case report, "Prior to this experiment, for over two years, there has not been more than a day, at least during the winter months, when she has not required some Vicodin."
Her pain ceased within a few days of resuming GenoMed's treatment in February, 2006. In June, 2006, her physician intentionally stopped GenoMed's treatment to see what would happen. The patient's pain recurred within a week. When she resumed GenoMed's treatment, her pain again stopped within a few days. She has been pain-free on GenoMed's treatment for a total of 14 months now.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Although only a single patient, she satisfied a rigorous clinical test. As long as the patient was on our treatment, her pain was gone. On two occasions, one accidental and one deliberate, our treatment was stopped. On both occasions her pain recurred promptly, only to disappear quickly after treatment was resumed. She hasn't needed pain pills in over a year; previously she took an average of four Vicodins a day. It doesn't get much more convincing than this."
Added Dr. Moskowitz, "We'd like to see if our results hold up with additional patients. Until now, there hasn't been effective treatment for sickle cell disease."
GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including sickle cell disease. This case report was published in the March issue of the Journal of the National Medical Association (http://www.nmanet.org/images/uploads/Publications/CR0276.pdf). To enroll in GenoMed's sickle cell disease trial, please contact Dr. Moskowitz.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
David W. Moskowitz MD, 314-983-9933
Posted: March 2007